Myeloma Trial, Recruiting NCT06871176 Sponsor: University Health Network, Toronto Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06871176
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are older than 18 years of age
  • People who have been clinically diagnosed with a specific form of multiple myeloma (a type of blood cancer) — including types that produce little or no detectable protein, or where the disease has spread outside the bone marrow — diagnosed using internationally recognised criteria
  • People who have received no more than one course of treatment for their condition

Who may not be able to join:

  • People for whom MRI or a type of nuclear imaging scan (PET/CT using a radioactive sugar called 18F-FDG) is not considered safe, according to the guidelines of the trial site
  • People who are pregnant (the trial site will check this according to their standard procedures)
  • People who are unable to lie still on their stomach for at least 30 minutes during an MRI or PET/CT scan
  • People who are unwilling to use contraception during the study, or who are currently breastfeeding
  • People who are unable to give their own informed consent to participate
  • People who have a known allergy or sensitivity to any ingredient in the investigational imaging agent used in this trial (called [68Ga]Ga-PentixaFor)
  • People who have also been diagnosed with another blood cancer at the same time, such as lymphoma or leukaemia

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Patrick Veit-Haibach, MD, University Health Network, Toronto

Phone: 416-340-4800 Ext. 6085

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
22 April 2025
Est. completion
4 March 2028

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Diagnostic Accuracy of CXCR4-targeted [68Ga]Ga-PentixaFor PET/MR Imaging Compared to Standard of Care Imaging

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov